Mayzent (Siponimod) Patent Expiration, LOE Window & CMS Spending

Mayzent (Siponimod) by Novartis: FDA Orange Book core substance LOE 2028-08-27 (last listed 2036-04-23), 0 AB generics, $92.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN209884 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-08-27
Last Listed Patent or Exclusivity Date2036-04-23
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$92.0M
2024 Medicare Part D Spend$75.8M
2024 Medicaid Spend$16.2M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 20.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.